Myeloid-derived suppressor cells in immunity and autoimmunity

Expert Review of Clinical Immunology

Volumn 11, Issue 8, 2015, Pages 911-919

  Yang, Hui ^a   Bi, Yujing ^b   Han, Fei ^a   Lu, Yun ^a   Wang, Jian ^a   Zhang, Zhengguo ^a   Liu, Guangwei ^a  

^a FUDAN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

autoimmune disease; immune modulation; innate immunity; MDSCs; T cells

Indexed keywords

ARGINASE 1; CCAAT ENHANCER BINDING PROTEIN BETA; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 3; L SELECTIN; MYELOID DIFFERENTIATION FACTOR 88; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN KINASE C BETA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UROKINASE; VASCULOTROPIN;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; BONE MARROW CELL; CELL DIFFERENTIATION; CELL THERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; MULTIPLE SCLEROSIS; MYELOID DERIVED SUPPRESSOR CELL; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNE TOLERANCE; IMMUNITY; MYELOID CELLS;

EID: 84937218781     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1052794     Document Type: Review

References (64)

1. Liu G, Bi Y, Shen B, et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis. Cancer Res 2014; 74(3): 727-37
2. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2010; 12(6): 417-30
3. Raber P, Ochoa AC, Rodriguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012; 41(6-7): 614-34
4. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22(2): 238-44
5. Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138(2): 105-15
6. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69(4): 1553-60
7. Liu G, Bi Y, Wang R, et al. Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells1. J Immunol 2014; 192(7): 3068-79
8. Zhang Y, Bi Y, Yang H, et al. mTOR limits the recruitment of CD11b+Gr1+Ly6Chigh myeloid-derived suppressor cells in protecting against murine immunological hepatic injury. J Leukoc Biol 2014
9. Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70(11): 4335-45
10. Gowda M, Godder K, Kmieciak M, et al. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011; 9: 170
11. Hanson EM, Clements VK, Sinha P, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009; 183(2): 937-44
12. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173(6): 3844-54
13. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70(9): 3526-36
14. Qu P, Du H, Li Y, et al. Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic inflammation and adenocarcinoma in the lung. J Immunol 2009; 182(3): 1648-59
15. Foell D, Wittkowski H, Vogl T, et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81(1): 28-37
16. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205(10): 2235-49
17. Farren MR, Carlson LM, Lee KP. Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res 2010; 46(1-3): 165-76
18. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116(10): 2777-90
19. Greifenberg V, Ribechini E, Rossner S, et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009; 39(10): 2865-76
20. Arora M, Poe SL, Oriss TB, et al. TLR4/MyD88-induced CD11b+Gr-1 int F4/80+non-migratory myeloid cells suppress Th2 effector function in the lung. Mucosal Immunol 2010; 3(6): 578-93
21. Zanzinger K, Schellack C, Nausch N, et al. Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology 2009; 128(2): 185-95
22. Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006; 25(3): 323-31
23. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14(5): 408-19
24. Hirai H, Zhang P, Dayaram T, et al. C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol 2006; 7(7): 732-9
25. Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2011; 32(6): 790-802
26. Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32(6): 790-802
27. Rodriguez D, Silvera R, Carrio R, et al. Tumor microenvironment profoundly modifies functional status of macrophages: peritoneal and tumor-associated macrophages are two very different subpopulations. Cell Immunol 2010; 283(1-2): 51-60
28. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235(1): 267-85
29. Olechnowicz SW, Edwards CM. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res 2010; 74(6): 1625-31
30. Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7(9): 678-89
31. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12(4): 253-68
32. Angelini G, Gardella S, Ardy M, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA 2002; 99(3): 1491-6
33. Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70(1): 68-77
34. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1- dependent mechanism that is up-regulated by interleukin-13. Blood 2010; 116(25): 5738-47
35. Bronte V, Serafini P, Mazzoni A, et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003; 24(6): 302-6
36. Rodriguez PC, Zea AH, Culotta KS, et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 2002; 277(24): 21123-9
37. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13(7): 828-35
38. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202(7): 919-29
39. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66(2): 1123-31
40. Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68(13): 5439-49
41. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70(1): 99-108
42. Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12(4): 239-52
43. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198(11): 1741-52
44. Ko HJ, Lee JM, Kim YJ, et al. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 2009; 182(4): 1818-28
45. Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13(2 Pt 2): 721s-6s
46. Kmieciak M, Basu D, Payne KK, et al. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 2011; 187(2): 708-17
47. De Santo C, Salio M, Masri SH, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008; 118(12): 4036-48
48. Li R, Deng F, Fu Y, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys. Pharmacology 2010; 85(6): 319-27
49. Sinha P, Clements VK, Bunt SK, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179(2): 977-83
50. Mildner A, Mack M, Schmidt H, et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009; 132(Pt 9): 2487-500
51. King IL, Dickendesher TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009; 113(14): 3190-7
52. Bowen JL, Olson JK. Innate immune CD11b+Gr-1+ cells, suppressor cells, affect the immune response during Theiler's virus-induced demyelinating disease. J Immunol 2009; 183(11): 6971-80
53. Gorham JD, Lin JT, Sung JL, et al. Genetic regulation of autoimmune disease: BALB/c background TGF-beta 1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J Immunol 2001; 166(10): 6413-22
54. Gold DP, Schroder K, Powell HC, et al. Nitric oxide and the immunomodulation of experimental allergic encephalomyelitis. Eur J Immunol 1997; 27(11): 2863-9
55. Kahn DA, Archer DC, Gold DP, et al. Adjuvant immunotherapy is dependent on inducible nitric oxide synthase. J Exp Med 2001; 193(11): 1261-8
56. Cross AH, Ramsbottom MJ, Lyons JA. NOS2 regulates cytokine production and VLA-4 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006; 173(1-2): 79-86
57. Olson JK, Girvin AM, Miller SD. Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler's virus. J Virol 2001; 75(20): 9780-9
58. Sander LE, Sackett SD, Dierssen U, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010; 207(7): 1453-64
59. Cripps JG, Gorham JD. MDSC in autoimmunity. Int Immunopharmacol 2011; 11(7): 789-93
60. Cripps JG, Wang J, Maria A, et al. Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology 2010; 52(4): 1350-9
61. Longhi MS, Mitry RR, Samyn M, et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009; 50(1): 130-42
62. Westendorf AM, Fleissner D, Deppenmeier S, et al. Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells. Gastroenterology 2006; 131(2): 510-24
63. Zhou Z, French DL, Ma G, et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells 2010; 28(3): 620-32
64. Haile LA, von Wasielewski R, Gamrekelashvili J, et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008; 135(3): 871-81